Neoadjuvant nivolumab plus ipilimumab results in a substantial pathological response in most patients with mismatch repair–deficient colon cancer and appears to be safe.
The New England Journal of Medicine: Search Results in Gastroenterology
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer
